Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan
doi: https://doi.org/10.1101/2021.08.06.21261707

Article Information

doi 
https://doi.org/10.1101/2021.08.06.21261707
History 
  • August 9, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Arjun Puranik1,+,
  2. Patrick J. Lenehan1,+,
  3. Eli Silvert1,
  4. Michiel J.M. Niesen1,
  5. Juan Corchado-Garcia1,
  6. John C. O’Horo2,
  7. Abinash Virk2,
  8. Melanie D. Swift2,
  9. John Halamka2,
  10. Andrew D. Badley2,
  11. A.J. Venkatakrishnan1 and
  12. Venky Soundararajan1,*
  1. 1nference, Cambridge, Massachusetts 02139, USA
  2. 2Mayo Clinic, Rochester, Minnesota 55902, USA
  1. ↵*Correspondence to: Venky Soundararajan (venky{at}nference.net)

  1. ↵+ These authors contributed equally

Back to top
Posted August 09, 2021.
Download PDF
Data/Code
Email
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan
medRxiv 2021.08.06.21261707; doi: https://doi.org/10.1101/2021.08.06.21261707
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area